| INTRODUCTION
Coeliac disease (CD) is a systemic immune-mediated disorder that develops in genetically predisposed individuals after gluten ingestion. 1 Although CD is a complex multifactorial disease, two key points are crucial in its pathogenesis: gluten resistance to gastrointestinal digestion and gluten deamidation by tissue transglutaminase enzyme (tTG). These key factors increase the ability of gluten peptides to activate an adaptive CD4+ T cell-mediated response. 2 In the gut of coeliac patients, gluten-specific CD4+ T lymphocytes strongly recognise deamidated peptides and activate an immune response that serves a central role in the induction and maintenance of mucosal inflammation. 3 In recent years, an innovative method for exploring the pathogenesis of CD and investigating gluten-specific T lymphocytes has been proposed by Anderson and co-workers. 4 This approach is based on a short-term (3 day) oral gluten challenge (SGC) that enables the transient mobilisation of intestinal gluten-specific CD4+
T cells in the peripheral blood of coeliac patients who are already on a gluten-free diet (GFD). These lymphocytes can be easily detected by the enzyme-linked immunospot (ELISPOT) assay [4] [5] [6] or tetramer technology. 7, 8 Because gluten is the triggering factor for CD, its exclusion from the diet of a person with CD induces both clinical and histological remission; it is the only treatment available. However, the negative impact of a GFD on a patient's quality of life 9 combined with the high content in lipids and the vitamin and fibre deficiencies of manufactured gluten-free products 10, 11 have encouraged research on new alternative therapeutic strategies 12 for the treatment of CD.
We previously demonstrated that the detoxification of natural wheat flour using selected sourdough, lactobacilli and fungal proteases is an efficient approach to degrading gluten epitopes and reducing the remaining gluten in the final product to less than 10 ppm. 13 CD subjects in remission who consumed bread made with fully hydrolysed gluten for 60 days did not exhibit any sign of relapse (alteration in anti-tTG2 antibody levels or histological mucosal change) of the disease. 14 In this study, we aimed to confirm the absence of immunogenicity of treated wheat flour in vitro using T cell lines (TCLs) that were isolated from the intestinal mucosa of coeliac patients and assess whether a short-term oral challenge with hydrolysed wheat flour in vivo was able to recall a peripheral T cell response to natural nonhydrolysed gliadin. We compared these responses with the responses elicited after a brief consumption of natural wheat flour.
| MATERIALS AND METHODS

| Patients and in vivo wheat challenge procedure
Twenty HLA-DQ2.5 coeliac subjects (14 female subjects and six male subjects; mean age 16.9 years, and age range 12-24 years) who maintained a GFD for at least 3 years (range 3-20 years) and were in clinical remission were enrolled in this study ( Table 1 ). The diagnosis of CD was posed according to the 1990 ESPGHAN criteria, and the patients were regularly followed at the Department of Pediatrics of the University Hospital "Federico II" of Naples. Patients and their parents, in the case of young children, were informed about the objective of the study and provided their full consent. The serum level of anti-tTG2 antibodies (IgA) was immediately measured prior to the start of the challenge (day 0) using an enzyme-linked immunosorbent assay (ELISA) with a commercial kit (Eu tTg IgA;
Eurospital, Trieste, Italy). The results were interpreted according to the manufacturer's instructions: negative (<9 U/mL), borderline (9-16 U/mL), and positive (>16 U/mL). At the start of the challenge, 14
patients were seronegative for anti-tTG2, and five patients had low positive (<35 U/mL) antibody titres. In one patient, the anti-tTG2
IgA levels were not measured but this patient showed an anti-endomysial antibody (EMA)-negative profile. However, the careful monitoring of their diets by a dietitian enabled the assumption of a strict adherence to a GFD. Patients were randomised into two groups ( Anti-tTG sensitivity: negative <9 U/mL, border line in the range 9-16 U/mL, positive >16 gluten-free diet, gluten-free diet.
The protocol for the study was approved by the Ethical Committee of the Department of Pediatrics of the University of Naples, "Federico II" (prot. N°95/03/E2).
| Hydrolysis of gluten during wheat sourdough fermentation
The The sourdough was fermented for 48 hours at 37°C. Spray-drying was performed to remove the water, and the milled flours were used to produce the baked goods.
| Antigen preparation
Gliadins were extracted from the commercial wheat flour Sagittarium (natural gliadin) and the hydrolysed wheat flour (hydrolysed gliadin) according to Wieser et al. 15 and enzymatically digested with pepsin and trypsin (PT), as previously described. 16 A 33-mer peptide that contains the DQ2.5-glia-a1/2 epitopes was synthesised by solidphase automated flow, as described elsewhere. 17 Both PT-gliadin (indicated as gliadin) and the 33-mer were deamidated with guinea pig tTG, as previously reported. 17 A cytotoxicity assay on donor peripheral blood mononuclear cells (PBMCs) confirmed the absence of cell toxicity of the gliadin preparation tested on CD patients.
| Intestinal T cell assays
Polyclonal gliadin-specific TCLs that were previously isolated by jejunal biopsies of three HLA-DQ2.5 adult CD patients (#1, #2 and #3) 17 were assayed for responses to the deamidated form of both natural and hydrolysed gliadins. The immune responses were evaluated either by detection of INF-c production by the ELISA assay and proliferation assays, as previously described. 16 Our results indicated that all TCLs positively reacted to natural gliadin with a variable intensity. As in the case of TCL #2, the INF-c average value to gliadin was 1358AE21 pg/mL and 221AE0.1 pg/mL in response to medium alone ( Figure 1A ), whereas the INF-c production elicited in this TCL by hydrolysed gliadin was not dissimilar to the level detected at the baseline.
Similar results were observed in the proliferation assays using [ 3 H]thymidine. Natural gliadin-induced proliferative response in all analysed TCLs. As shown in Figure 1B , in the case of TCL #2, an average cpm value of 9360AE10 was obtained in response to gliadin, whereas a cpm value of 5527AE716 was observed in response to the medium alone. Conversely, no proliferative response was generated against the hydrolysed gliadin.
| Peripheral blood immune response after the short-term oral challenge with hydrolysed wheat
Ten DQ2 positive subjects who were affected by CD participated in the study (Table 1) 
| Peripheral blood immune response after short-term oral challenge with natural wheat
Ten DQ2 positive coeliac patients (Table 1) (P=.048) ( Figure 3B ).
| DISCUSSION
Currently, a gluten-free diet is the only therapy that is available for coeliac patients; however, its limitations have encouraged research on new alternative therapeutic strategies. 19 We recently focused our attention on a complex mixture of selected lactobacilli and fungal proteases that can cleave gluten in smaller peptides that are unable to activate any immune response during fermentation. 13 The objective of this study was to confirm the safety of this type at any of the concentrations tested.
In the next step, we evaluated the effect of hydrolysed wheat flour in vivo by monitoring the mobilisation of gluten-reactive T lymphocytes from the intestinal mucosa to the peripheral blood of ten DQ2.5 positive CD patients who were already on a GFD after a short-term oral challenge with hydrolysed wheat. We compared these responses with the responses elicited in another ten DQ2.5
positive CD patients after a short-term oral challenge with natural wheat. According to our expectation, we observed that natural glu- is sufficient for triggering an intestinal immune response in patients with a diagnosis of full-blown CD. 24 Conversely, we are able to overcome this risk using a mixture of proteases that degrade gluten during fermentation.
Our work highlights the utility of the short-term oral challenge as a highly useful tool for the validation of new therapies. The short-term oral challenge enables us to easily monitor the immune responses of CD patients in peripheral blood. It has been primarily employed to identify immunogenic gluten peptides 25, 26 and some papers have demonstrated that it could be helpful in the diagnosis of ambiguous cases of CD using the tetramers technique to detect gluten-reactive T cells. 7, 8 We support the idea that the short-term oral challenge is also a useful tool to validate the efficacy of new therapeutic strategies as an alternative to the invasive small bowel biopsy performed after a long-term gluten exposure (at least 2 weeks in an adult 27 ). However, other studies are required to compare the two approaches. Currently, only one other group has employed this technique to validate the efficacy of another therapeutic strategy: the effect of ALV003 pre-digestion of gluten. 28 In conclusion, via the innovative approach of the short-term oral challenge, we demonstrated that the pre-treatment of natural flour with selected lactobacilli and fungal proteases completely abolishes any immune stimulatory properties of gluten and can be suggested as an alternative therapeutic strategy for CD.
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